# American Regent, Inc. clinical trials: 53 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 53 trials with American Regent, Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by American Regent, Inc.: 53 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/american-regent-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 53
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 53, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 15, 2024 | NCT06690450 | Safety and Tolerability of 200mg and 100mg of Venofer Administered to Hemodialysis(HD) Patients | American Regent, Inc. | Phase 4 | Completed | Hemodialysis | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06690450) |
| January 10, 2023 | NCT05677126 | Tralement vs. Fixed-dose Trace Element Combination Product in Patients \>3 to 17 Years of Age Requiring Long-term PN | American Regent, Inc. | Phase 4 | Withdrawn | Manganese Safety in Pediatric Patients | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05677126) |
| December 22, 2022 | NCT05661682 | Tralement Versus a Fixed-dose Trace Element Combination Product to Evaluate Manganese Safety | American Regent, Inc. | Phase 4 | Withdrawn | Manganese Safety in Adults | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05661682) |
| July 20, 2021 | NCT04968379 | Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency Anemia | American Regent, Inc. | Phase 2 | Withdrawn | Iron Deficiency, Anaemia | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04968379) |
| February 17, 2020 | NCT04269707 | Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral... | American Regent, Inc. | Phase 3 | Completed | Iron Deficiency Anemia | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04269707) |
| May 14, 2018 | NCT03523117 | Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA | American Regent, Inc. | Phase 3 | Completed | Iron Deficiency Anemia | 79 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03523117) |
| January 31, 2017 | NCT03037931 | Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-Study | American Regent, Inc. | Phase 3 | Completed | Heart Failure, Iron-deficiency | 3,065 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03037931) |
| July 11, 2016 | NCT02826681 | Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia | American Regent, Inc. | Phase 2 | Terminated | Restless Legs Syndrome (RLS) | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02826681) |
| August 18, 2015 | NCT02527213 | Double-blind Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic Arteriolopathy | American Regent, Inc. | Phase 3 | Withdrawn | Calciphylaxis, Calcific Uremic Arteriolopathy | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02527213) |
| July 9, 2015 | NCT02492672 | Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease | American Regent, Inc. | Observational | Completed | Chronic Kidney Disease | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02492672) |
| June 23, 2015 | NCT02478281 | Safety, Tolerability, and Pharmacokinetic Study of Methylene Blue Following a 1 mg/kg Intravenous Dose in Healthy Adults | American Regent, Inc. | Phase 1 | Completed | Methemoglobinemia, Congenital Methemoglobinemia | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02478281) |
| May 25, 2015 | NCT02453334 | Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer® | American Regent, Inc. | Phase 3 | Completed | Cancer and Chemotherapy Related Anemia | 244 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02453334) |
| April 7, 2015 | NCT02410213 | A Study to Characterize the PK and PD Profile of IV FCM in Pediatric Subjects 1-17 Years Old With IDA | American Regent, Inc. | Phase 2 | Completed | Iron Deficiency Anemia (IDA) | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02410213) |
| April 6, 2015 | NCT02409459 | Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia | American Regent, Inc. | Phase 2 | Completed | Iron Deficiency, Fibromyalgia | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02409459) |
| March 24, 2015 | NCT02397057 | Placebo-Controlled Study to Investigate the Efficacy & Safety of Injectafer in the Treatment of RLS | American Regent, Inc. | Phase 3 | Completed | Restless Legs Syndrome (RLS) | 209 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02397057) |
| March 13, 2014 | NCT02086968 | Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to... | American Regent, Inc. | Phase 4 | Completed | Iron Deficiency Anemia Secondary to IBD or Gastric Bypass | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02086968) |
| November 14, 2013 | NCT01984554 | Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency Anemia | American Regent, Inc. | Observational | Completed | Iron Deficiency Anemia (IDA) | 551 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01984554) |
| September 25, 2013 | NCT01950247 | Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron | American Regent, Inc. | Phase 4 | Completed | Iron Deficiency Anemia (IDA) | 1,025 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01950247) |
| March 27, 2013 | NCT01819610 | Pharmacokinetics, Safety, and Efficacy of SPRIX in 12 to 17 Year Old Patients vs. Adult Patients Undergoing Open Surgical Procedures | American Regent, Inc. | Phase 3 | Completed | Pain | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01819610) |
| June 27, 2011 | NCT01382901 | Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS) | American Regent, Inc. | Phase 2 | Completed | Restless Legs Syndrome (RLS) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01382901) |
| June 3, 2011 | NCT01365624 | Safety and Pharmacokinetics Study of Intranasal Ketorolac in Elderly and Nonelderly Adult Healthy Subjects | American Regent, Inc. | Phase 1 | Completed | Healthy Subjects | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01365624) |
| May 10, 2011 | NCT01351090 | Study of the Safety, Tolerability and Analgesic Efficacy of Multiple Doses of Ketorolac Tromethamine (IN) for Postoperative Pain | American Regent, Inc. | Phase 2 | Completed | Postoperative Pain | 127 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01351090) |
| March 2, 2011 | NCT01307007 | Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding | American Regent, Inc. | Phase 2 | Completed | Iron Deficiency Anemia | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01307007) |
| February 7, 2011 | NCT01290315 | Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women | American Regent, Inc. | Phase 2 | Completed | Iron Deficiency Anemia | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01290315) |
| February 7, 2011 | NCT01290302 | Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza | American Regent, Inc. | Phase 1 | Completed | Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01290302) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 3 |
| Phase 2 | 15 |
| Phase 3 | 26 |
| Phase 4 | 7 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 45 |
| Withdrawn | 5 |
| Terminated | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Anemia | 18 |
| Anemia, Iron-Deficiency | 12 |
| Restless Legs Syndrome | 5 |
| Renal Insufficiency, Chronic | 5 |
| Melanoma | 3 |
| Neoplasms | 2 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Iron Deficiencies | 1 |
| Fibromyalgia | 1 |
| Heart Failure | 1 |
| Myelodysplastic Syndromes | 1 |
| Primary Myelofibrosis | 1 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 |
| Liver Neoplasms | 1 |
| Menorrhagia | 1 |
| Methemoglobinemia | 1 |
| Congenital Methemoglobinemia | 1 |
| Pain, Postoperative | 1 |
| Calciphylaxis | 1 |
| Renal Insufficiency | 1 |
| Pain | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Basque restaurants in the United States](https://specstream.ai/data/businesses/basque-restaurants/united-states)
- [American restaurants in the United States](https://specstream.ai/data/businesses/american-restaurants/united-states)
- [Turkish restaurants in the United States](https://specstream.ai/data/businesses/turkish-restaurants/united-states)
- [Social media agencies in the United States](https://specstream.ai/data/businesses/social-media-agencies/united-states)
- [Private schools in the United States](https://specstream.ai/data/businesses/private-schools/united-states)
- [Office supply stores in the United States](https://specstream.ai/data/businesses/office-supply-stores/united-states)
